| RGS4 — Regulator of G Protein Signaling 4 | |
|---|---|
| Symbol | RGS4 |
| Full Name | Regulator of G Protein Signaling 4 |
| Chromosome | 1q23.3 |
| NCBI Gene | 5999 |
| OMIM | 602514 |
| Ensembl | ENSG00000117408 |
| UniProt | P49798 |
| Diseases | Schizophrenia, Parkinson's Disease, Depression, Chronic Pain |
| Expression | Prefrontal cortex, Striatum, Hippocampus |
Rgs4 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
RGS4 (Regulator of G Protein Signaling 4) is a gene located on chromosome 1q23.3 that encodes a brain-specific GTPase-activating protein for G protein-coupled receptor (GPCR) signaling. RGS4 is one of the most abundantly expressed RGS proteins in the central nervous system, with particularly high expression in the prefrontal cortex, striatum, and hippocampus [Citation 1]. The protein plays a critical role in modulating Gαi/o and Gαq subunit signaling by accelerating the intrinsic GTPase activity, thereby rapidly terminating G protein-mediated signal transduction [Citation 2].
RGS4 has emerged as an important regulator of dopaminergic, GABAergic, serotonergic, and cholinergic signaling in the brain. Dysregulation of RGS4 has been implicated in several neuropsychiatric and neurodegenerative disorders, making it a potential therapeutic target for conditions including schizophrenia, Parkinson's disease, addiction, and chronic pain [Citation 3][Citation 4].
RGS4 functions as a GTPase-activating protein (GAP) that:
In the central nervous system, RGS4 regulates:
Dopamine Signaling
GABAergic Signaling
Opioid Receptor Signaling
Muscarinic Acetylcholine Signaling
RGS4 shows brain-specific expression with highest levels in:
Expression is activity-dependent and regulated by:
RGS4 has been extensively studied in schizophrenia:
In PD, RGS4 plays important roles:
RGS4 modulates reward circuitry:
RGS4 regulates:
RGS4 affects:
RGS4 modulators have therapeutic potential for:
| Condition | Therapeutic Approach |
|---|---|
| Schizophrenia | Cognitive enhancement, address negative symptoms |
| Parkinson's Disease | Manage motor complications, reduce dyskinesias |
| Addiction | Reduce drug craving and relapse |
| Chronic Pain | Enhance opioid analgesic efficacy |
| Depression | Modulate monoaminergic signaling |
Small molecule RGS4 inhibitors and allosteric modulators are under development for CNS disorders [Citation 10].
The study of Rgs4 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Page updated: 2026-03-05